Loading…
Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide
•A pig model of gut injury was established by injecting Escherichia coli LPS.•PEGylated pGLP-2 infusion ameliorated intestinal injury by increasing the villus height/crypt depth ratio and decreasing the pro-inflammatory cytokines levels.•The therapeutic effects of PEG–pGLP-2 may be associated with r...
Saved in:
| Published in: | Peptides (New York, N.Y. : 1980) N.Y. : 1980), 2014-08, Vol.58, p.7-13 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c434t-f23aa8d40a0ee33a9cd36227eac2ee967f60743eb5039b8ec82aec3d92d337ff3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c434t-f23aa8d40a0ee33a9cd36227eac2ee967f60743eb5039b8ec82aec3d92d337ff3 |
| container_end_page | 13 |
| container_issue | |
| container_start_page | 7 |
| container_title | Peptides (New York, N.Y. : 1980) |
| container_volume | 58 |
| creator | Qi, Ke-ke Wu, Jie Xu, Zi-wei |
| description | •A pig model of gut injury was established by injecting Escherichia coli LPS.•PEGylated pGLP-2 infusion ameliorated intestinal injury by increasing the villus height/crypt depth ratio and decreasing the pro-inflammatory cytokines levels.•The therapeutic effects of PEG–pGLP-2 may be associated with reduced cell apoptosis.
This study aims to evaluate the therapeutic effect of polyethylene glycosylated porcine glucagon-like peptide-2 (pGLP-2), a long-acting form of pGLP-2, in lipopolysaccharide (LPS)-challenged piglets. Eighteen 21-day-old weaning piglets were randomly assigned into three groups: control (saline solution), LPS (100μg/kg LPS), and PEG–pGLP-2 (10nmol/kg PEG–pGLP-2+100μg/kg LPS). All treatments were administered intraperitoneally. Compared with the control treatment, LPS treatment significantly decreased (P0.05). Specifically, PEG–pGLP-2 infusion significantly increased the villus height/crypt depth ratio of the duodenum (P |
| doi_str_mv | 10.1016/j.peptides.2014.05.007 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1677933914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196978114001533</els_id><sourcerecordid>1547525838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-f23aa8d40a0ee33a9cd36227eac2ee967f60743eb5039b8ec82aec3d92d337ff3</originalsourceid><addsrcrecordid>eNqNkc1uEzEYRS0EoqHlFSov2czgv_HPDlSFtlIlWNC15Xg-TxycmcGeUOXtcZWUbVl54XPvlb6D0DUlLSVUft61M8xL7KG0jFDRkq4lRL1BK6oVbzoqzVu0ItTIxihNL9CHUnaEECGMfo8umNBKKKJXKK9DAL8UPAX8Y317TG6BHs9T9nEEPKSDd8M0Nin-AnxebBhetpDdfMRxxE_gxjgOeI5Dgtrjty4lGIfa8hSXLU5xnuYpHYvz9SvX_BV6F1wq8PH8XqLHb-ufN3fNw_fb-5uvD40XXCxNYNw53QviCADnzvieS8YUOM8AjFRBEiU4bDrCzUaD18yB571hPecqBH6JPp165zz9PkBZ7D4WDym5EaZDsVQqZTg3VLyOdrJeS1LS_QcqVMc6zXVF5Qn1eSolQ7BzjnuXj5YS-2zR7uyLRfts0ZLOVos1eH3eOGz20P-LvWirwJcTAPV-fyJkW3yE0UMfc7Vp-ym-tvEX9MuzKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547525838</pqid></control><display><type>article</type><title>Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide</title><source>ScienceDirect Journals</source><creator>Qi, Ke-ke ; Wu, Jie ; Xu, Zi-wei</creator><creatorcontrib>Qi, Ke-ke ; Wu, Jie ; Xu, Zi-wei</creatorcontrib><description><![CDATA[•A pig model of gut injury was established by injecting Escherichia coli LPS.•PEGylated pGLP-2 infusion ameliorated intestinal injury by increasing the villus height/crypt depth ratio and decreasing the pro-inflammatory cytokines levels.•The therapeutic effects of PEG–pGLP-2 may be associated with reduced cell apoptosis.
This study aims to evaluate the therapeutic effect of polyethylene glycosylated porcine glucagon-like peptide-2 (pGLP-2), a long-acting form of pGLP-2, in lipopolysaccharide (LPS)-challenged piglets. Eighteen 21-day-old weaning piglets were randomly assigned into three groups: control (saline solution), LPS (100μg/kg LPS), and PEG–pGLP-2 (10nmol/kg PEG–pGLP-2+100μg/kg LPS). All treatments were administered intraperitoneally. Compared with the control treatment, LPS treatment significantly decreased (P<0.05) the villus heights of the duodenum and jejunum, as well as the villus height/crypt depth ratio of the jejunum. However, PEG–pGLP-2 therapy reduced these effects (P>0.05). Specifically, PEG–pGLP-2 infusion significantly increased the villus height/crypt depth ratio of the duodenum (P<0.05) compared with LPS treatment. Compared with the control treatment, LPS treatment significantly increased (P<0.05) the mRNA expression levels of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) in the jejunum. However, PEG–pGLP-2 therapy reduced these effects (P<0.05). Specifically, PEG–pGLP-2 infusion significantly decreased (P<0.05) the mRNA expression levels of interleukin (IL)-8 and TNF-α in the duodenum and jejunum, IL-10 in the duodenum, and IFN-γ in the jejunum compared with the LPS treatment. LPS treatment increased the caspase-3 activity of the ileum mucosal (P<0.05), and this effect was significantly reduced by PEG–pGLP-2 treatment. These results indicate that PEG–pGLP-2 infusion alleviates the severity of intestinal injury in weaning piglets by reducing the secretion of inflammatory cytokines and the caspase-3 activity, and increasing the villus height/crypt depth ratio.]]></description><identifier>ISSN: 0196-9781</identifier><identifier>EISSN: 1873-5169</identifier><identifier>DOI: 10.1016/j.peptides.2014.05.007</identifier><identifier>PMID: 24874708</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Caspase-3 ; Crypts ; Cytokines ; Gene expression ; Glucagon-Like Peptide 2 - pharmacology ; Inflammatory cytokines ; Infusion ; Injury prevention ; Interferon-gamma - metabolism ; Interleukin-8 - metabolism ; Jejunum - metabolism ; Jejunum - pathology ; Lipopolysaccharides - toxicity ; PEGylated ; Piglet ; Polyethylene Glycols - pharmacology ; Porcine glucagon-like peptide-2 ; Saline solutions ; Secretions ; Swine ; Therapy ; Tight junction protein ; Tumor Necrosis Factor-alpha - metabolism ; Weaning</subject><ispartof>Peptides (New York, N.Y. : 1980), 2014-08, Vol.58, p.7-13</ispartof><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-f23aa8d40a0ee33a9cd36227eac2ee967f60743eb5039b8ec82aec3d92d337ff3</citedby><cites>FETCH-LOGICAL-c434t-f23aa8d40a0ee33a9cd36227eac2ee967f60743eb5039b8ec82aec3d92d337ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24874708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qi, Ke-ke</creatorcontrib><creatorcontrib>Wu, Jie</creatorcontrib><creatorcontrib>Xu, Zi-wei</creatorcontrib><title>Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide</title><title>Peptides (New York, N.Y. : 1980)</title><addtitle>Peptides</addtitle><description><![CDATA[•A pig model of gut injury was established by injecting Escherichia coli LPS.•PEGylated pGLP-2 infusion ameliorated intestinal injury by increasing the villus height/crypt depth ratio and decreasing the pro-inflammatory cytokines levels.•The therapeutic effects of PEG–pGLP-2 may be associated with reduced cell apoptosis.
This study aims to evaluate the therapeutic effect of polyethylene glycosylated porcine glucagon-like peptide-2 (pGLP-2), a long-acting form of pGLP-2, in lipopolysaccharide (LPS)-challenged piglets. Eighteen 21-day-old weaning piglets were randomly assigned into three groups: control (saline solution), LPS (100μg/kg LPS), and PEG–pGLP-2 (10nmol/kg PEG–pGLP-2+100μg/kg LPS). All treatments were administered intraperitoneally. Compared with the control treatment, LPS treatment significantly decreased (P<0.05) the villus heights of the duodenum and jejunum, as well as the villus height/crypt depth ratio of the jejunum. However, PEG–pGLP-2 therapy reduced these effects (P>0.05). Specifically, PEG–pGLP-2 infusion significantly increased the villus height/crypt depth ratio of the duodenum (P<0.05) compared with LPS treatment. Compared with the control treatment, LPS treatment significantly increased (P<0.05) the mRNA expression levels of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) in the jejunum. However, PEG–pGLP-2 therapy reduced these effects (P<0.05). Specifically, PEG–pGLP-2 infusion significantly decreased (P<0.05) the mRNA expression levels of interleukin (IL)-8 and TNF-α in the duodenum and jejunum, IL-10 in the duodenum, and IFN-γ in the jejunum compared with the LPS treatment. LPS treatment increased the caspase-3 activity of the ileum mucosal (P<0.05), and this effect was significantly reduced by PEG–pGLP-2 treatment. These results indicate that PEG–pGLP-2 infusion alleviates the severity of intestinal injury in weaning piglets by reducing the secretion of inflammatory cytokines and the caspase-3 activity, and increasing the villus height/crypt depth ratio.]]></description><subject>Animals</subject><subject>Caspase-3</subject><subject>Crypts</subject><subject>Cytokines</subject><subject>Gene expression</subject><subject>Glucagon-Like Peptide 2 - pharmacology</subject><subject>Inflammatory cytokines</subject><subject>Infusion</subject><subject>Injury prevention</subject><subject>Interferon-gamma - metabolism</subject><subject>Interleukin-8 - metabolism</subject><subject>Jejunum - metabolism</subject><subject>Jejunum - pathology</subject><subject>Lipopolysaccharides - toxicity</subject><subject>PEGylated</subject><subject>Piglet</subject><subject>Polyethylene Glycols - pharmacology</subject><subject>Porcine glucagon-like peptide-2</subject><subject>Saline solutions</subject><subject>Secretions</subject><subject>Swine</subject><subject>Therapy</subject><subject>Tight junction protein</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Weaning</subject><issn>0196-9781</issn><issn>1873-5169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqNkc1uEzEYRS0EoqHlFSov2czgv_HPDlSFtlIlWNC15Xg-TxycmcGeUOXtcZWUbVl54XPvlb6D0DUlLSVUft61M8xL7KG0jFDRkq4lRL1BK6oVbzoqzVu0ItTIxihNL9CHUnaEECGMfo8umNBKKKJXKK9DAL8UPAX8Y317TG6BHs9T9nEEPKSDd8M0Nin-AnxebBhetpDdfMRxxE_gxjgOeI5Dgtrjty4lGIfa8hSXLU5xnuYpHYvz9SvX_BV6F1wq8PH8XqLHb-ufN3fNw_fb-5uvD40XXCxNYNw53QviCADnzvieS8YUOM8AjFRBEiU4bDrCzUaD18yB571hPecqBH6JPp165zz9PkBZ7D4WDym5EaZDsVQqZTg3VLyOdrJeS1LS_QcqVMc6zXVF5Qn1eSolQ7BzjnuXj5YS-2zR7uyLRfts0ZLOVos1eH3eOGz20P-LvWirwJcTAPV-fyJkW3yE0UMfc7Vp-ym-tvEX9MuzKA</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>Qi, Ke-ke</creator><creator>Wu, Jie</creator><creator>Xu, Zi-wei</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U5</scope><scope>8FD</scope><scope>L7M</scope></search><sort><creationdate>20140801</creationdate><title>Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide</title><author>Qi, Ke-ke ; Wu, Jie ; Xu, Zi-wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-f23aa8d40a0ee33a9cd36227eac2ee967f60743eb5039b8ec82aec3d92d337ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Caspase-3</topic><topic>Crypts</topic><topic>Cytokines</topic><topic>Gene expression</topic><topic>Glucagon-Like Peptide 2 - pharmacology</topic><topic>Inflammatory cytokines</topic><topic>Infusion</topic><topic>Injury prevention</topic><topic>Interferon-gamma - metabolism</topic><topic>Interleukin-8 - metabolism</topic><topic>Jejunum - metabolism</topic><topic>Jejunum - pathology</topic><topic>Lipopolysaccharides - toxicity</topic><topic>PEGylated</topic><topic>Piglet</topic><topic>Polyethylene Glycols - pharmacology</topic><topic>Porcine glucagon-like peptide-2</topic><topic>Saline solutions</topic><topic>Secretions</topic><topic>Swine</topic><topic>Therapy</topic><topic>Tight junction protein</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Weaning</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qi, Ke-ke</creatorcontrib><creatorcontrib>Wu, Jie</creatorcontrib><creatorcontrib>Xu, Zi-wei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Technology Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><jtitle>Peptides (New York, N.Y. : 1980)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qi, Ke-ke</au><au>Wu, Jie</au><au>Xu, Zi-wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide</atitle><jtitle>Peptides (New York, N.Y. : 1980)</jtitle><addtitle>Peptides</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>58</volume><spage>7</spage><epage>13</epage><pages>7-13</pages><issn>0196-9781</issn><eissn>1873-5169</eissn><abstract><![CDATA[•A pig model of gut injury was established by injecting Escherichia coli LPS.•PEGylated pGLP-2 infusion ameliorated intestinal injury by increasing the villus height/crypt depth ratio and decreasing the pro-inflammatory cytokines levels.•The therapeutic effects of PEG–pGLP-2 may be associated with reduced cell apoptosis.
This study aims to evaluate the therapeutic effect of polyethylene glycosylated porcine glucagon-like peptide-2 (pGLP-2), a long-acting form of pGLP-2, in lipopolysaccharide (LPS)-challenged piglets. Eighteen 21-day-old weaning piglets were randomly assigned into three groups: control (saline solution), LPS (100μg/kg LPS), and PEG–pGLP-2 (10nmol/kg PEG–pGLP-2+100μg/kg LPS). All treatments were administered intraperitoneally. Compared with the control treatment, LPS treatment significantly decreased (P<0.05) the villus heights of the duodenum and jejunum, as well as the villus height/crypt depth ratio of the jejunum. However, PEG–pGLP-2 therapy reduced these effects (P>0.05). Specifically, PEG–pGLP-2 infusion significantly increased the villus height/crypt depth ratio of the duodenum (P<0.05) compared with LPS treatment. Compared with the control treatment, LPS treatment significantly increased (P<0.05) the mRNA expression levels of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) in the jejunum. However, PEG–pGLP-2 therapy reduced these effects (P<0.05). Specifically, PEG–pGLP-2 infusion significantly decreased (P<0.05) the mRNA expression levels of interleukin (IL)-8 and TNF-α in the duodenum and jejunum, IL-10 in the duodenum, and IFN-γ in the jejunum compared with the LPS treatment. LPS treatment increased the caspase-3 activity of the ileum mucosal (P<0.05), and this effect was significantly reduced by PEG–pGLP-2 treatment. These results indicate that PEG–pGLP-2 infusion alleviates the severity of intestinal injury in weaning piglets by reducing the secretion of inflammatory cytokines and the caspase-3 activity, and increasing the villus height/crypt depth ratio.]]></abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24874708</pmid><doi>10.1016/j.peptides.2014.05.007</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0196-9781 |
| ispartof | Peptides (New York, N.Y. : 1980), 2014-08, Vol.58, p.7-13 |
| issn | 0196-9781 1873-5169 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1677933914 |
| source | ScienceDirect Journals |
| subjects | Animals Caspase-3 Crypts Cytokines Gene expression Glucagon-Like Peptide 2 - pharmacology Inflammatory cytokines Infusion Injury prevention Interferon-gamma - metabolism Interleukin-8 - metabolism Jejunum - metabolism Jejunum - pathology Lipopolysaccharides - toxicity PEGylated Piglet Polyethylene Glycols - pharmacology Porcine glucagon-like peptide-2 Saline solutions Secretions Swine Therapy Tight junction protein Tumor Necrosis Factor-alpha - metabolism Weaning |
| title | Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A02%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20PEGylated%20porcine%20glucagon-like%20peptide-2%20therapy%20in%20weaning%20piglets%20challenged%20with%20lipopolysaccharide&rft.jtitle=Peptides%20(New%20York,%20N.Y.%20:%201980)&rft.au=Qi,%20Ke-ke&rft.date=2014-08-01&rft.volume=58&rft.spage=7&rft.epage=13&rft.pages=7-13&rft.issn=0196-9781&rft.eissn=1873-5169&rft_id=info:doi/10.1016/j.peptides.2014.05.007&rft_dat=%3Cproquest_cross%3E1547525838%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c434t-f23aa8d40a0ee33a9cd36227eac2ee967f60743eb5039b8ec82aec3d92d337ff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1547525838&rft_id=info:pmid/24874708&rfr_iscdi=true |